Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorouracil/folinic acid - FivepHusion

Drug Profile

Fluorouracil/folinic acid - FivepHusion

Alternative Names: 5-fluorouracil/leucovorin; 5-FU/leucovorin; 5-FU/LV; Fluorodex; Fluorouracil/leucovorin; Folinic acid/5-fluorouracil; Leucovorin/5-fluorouracil; Leucovorin/5-FU; LV/5-FU

Latest Information Update: 02 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Wollongong
  • Developer Fivephusion
  • Class Antineoplastics; Chemoprotectants; Chemosensitisers; Formyltetrahydrofolates; Pyrimidinones; Small molecules
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 Jul 2023 FivepHusion enters into a clinical collaboration agreement with Allarity Therapeutics
  • 31 Jul 2023 FivepHusion plans a phase Ib/IIa trial in Colorectal cancer (First line therapy, Inoperable/ Unresectable, Metastatic disease) in H2 2023
  • 05 Oct 2020 Phase I/II trial is still ongoing for Solid tumours in Australia (FivepHusion Pipeline, October 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top